Histone Deacetylase Inhibition Blunts Ischemia/Reperfusion Injury by Inducing Cardiomyocyte Autophagy | Zendy

Min Xie | Zendy; Yongli Kong | Zendy; Wei Tan | Zendy; Herman I. May | Zendy; Pavan K. Battiprolu | Zendy; Zully Pedrozo | Zendy; Zhao V. Wang | Zendy; Cyndi R. Morales | Zendy; Xiang Luo | Zendy; Geoffrey Cho | Zendy; Nan Jiang | Zendy; Michael E. Jessen | Zendy; John J. Warner | Zendy; Sergio Lavandero | Zendy; Thomas G. Gillette | Zendy; Aslan T. Turer | Zendy; Joseph A. Hill | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Histone Deacetylase Inhibition Blunts Ischemia/Reperfusion Injury by Inducing Cardiomyocyte Autophagy

Author(s) -

Min Xie,

Yongli Kong,

Wei Tan,

Herman I. May,

Pavan K. Battiprolu,

Zully Pedrozo,

Zhao V. Wang,

Cyndi R. Morales,

Xiang Luo,

Geoffrey Cho,

Nan Jiang,

Michael E. Jessen,

John J. Warner,

Sergio Lavandero,

Thomas G. Gillette,

Aslan T. Turer,

Joseph A. Hill

Publication year - 2014

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.113.002416

Subject(s) - medicine , autophagy , histone deacetylase , reperfusion injury , ischemia , histone , pharmacology , microbiology and biotechnology , cardiology , apoptosis , biochemistry , biology , dna

Reperfusion accounts for a substantial fraction of the myocardial injury occurring with ischemic heart disease. Yet, no standard therapies are available targeting reperfusion injury. Here, we tested the hypothesis that suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor approved for cancer treatment by the US Food and Drug Administration, will blunt reperfusion injury.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research